Novo Nordisk Raises Annual Guidance as Wegovy Adoption Hits Record Highs

Key Facts

Global pharmaceutical giant Novo Nordisk has improved its full-year financial guidance, now projecting a maximum decline in annual profit and sales of 12%, down from the previously forecasted 13%. This upward revision was fueled by robust demand for its weight-loss medication, Wegovy, which continues to see the fastest take-up rate in the history of its class. Notably, a new pill version of Wegovy significantly boosted first-quarter sales and provided a key pillar for the revised outlook. The adjustment reflects sustained market confidence in innovative obesity treatments despite broader economic pressures. Investors remain focused on the company's capacity to scale production and expand its geographical footprint to meet unprecedented demand. Overall, the updated guidance reinforces a bullish long-term valuation for Novo Nordisk as it diversifies its product delivery formats.

Version History